Shares of Boston Scientific fell 31 cents, or 1.5 percent, to close at $20.22 Wednesday on the New York Stock Exchange. Boston Scientific spokesman Paul Donovan said officials at Guidant "understand and acknowledge the need for more timely and transparent communication." "We are committed to doing a better job of communicating with patients and physicians," he said. "We continue to implement new standards for product performance communication and to enhance our quality and design systems." Warning letter never sent Donovan confirmed the warning letter was never sent to doctors. The letter was first reported Wednesday by The New York Times, which intervened in the product liability lawsuit in attempt to seek access to records. A judge ordered the release of the documents on Monday.